WO1995014381A1 - Derives amphiphiles de guanidine - Google Patents

Derives amphiphiles de guanidine Download PDF

Info

Publication number
WO1995014381A1
WO1995014381A1 PCT/US1994/013428 US9413428W WO9514381A1 WO 1995014381 A1 WO1995014381 A1 WO 1995014381A1 US 9413428 W US9413428 W US 9413428W WO 9514381 A1 WO9514381 A1 WO 9514381A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
amphiphile
dna
compounds
amphiphiles
Prior art date
Application number
PCT/US1994/013428
Other languages
English (en)
Inventor
Timothy D. Heath
Igor Solodin
Original Assignee
Megabios Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megabios Corporation filed Critical Megabios Corporation
Priority to KR1019960702743A priority Critical patent/KR960705771A/ko
Priority to AU11842/95A priority patent/AU691226B2/en
Priority to JP7515172A priority patent/JPH09505808A/ja
Priority to EP95902642A priority patent/EP0730405A4/fr
Priority to NZ276975A priority patent/NZ276975A/en
Publication of WO1995014381A1 publication Critical patent/WO1995014381A1/fr
Priority to NO962074A priority patent/NO962074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms

Definitions

  • This invention relates to nitrogen containing amphiphiles for use in the preparation of liposomes and other lipid-containing carriers of pharmaceutical substances, including nucleic acids used in gene therapy.
  • Liposomes are one of a number of lipid-based materials used as biological carriers and have been used effectively as carriers in a number of pharmaceutical and other biological situations, particularly to introduce drugs, radiotherapeutic agents, enzymes, viruses, transcriptional factors and other cellular vectors into a variety of cultured cell lines and animals.
  • Successful clinical trials have examined the effectiveness of liposome-mediated drug delivery for targeting liposome-entrapped drugs to specific tissues and specific cell types. See, for example, U.S. patent No. 5,264,618, which describes a number of techniques for using lipid carriers, including the preparation of liposomes and pharmaceutical compositions and the use of such compositions in clinical situations.
  • Literature describing the use of liposomes as carriers for DNA include the following: (Friedmann (1989), supra; Brigham, et al., (1989) Am. J. Med. ScL, 298:278-281; Nabel, et al. (1990) Science, 249:1285-1288; Hazinski, et al. (1991) Am. J. Resp. Cell Molec. Biol., 4:206-209; and Wang and Huang (1987) Proc. Natl. Acad. Sci. (USA), 84:7851-7855); coupled to ligand-specific, cation-based transport systems (Wu and Wu (1988) J. Biol.
  • Cationic lipid carriers have been snown to mediate intracellular delivery of plasmid DNA (Feigner, et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413-7416); mRNA (Malone, et al., Proc. Natl. Acad. Sci. USA (1989) 86:6077-6081); and purified transcription factors (Debs, et al., J. Biol. Chem. (1990) 265: 10189-10192), in functional form.
  • Non-toxic, novel, amphiphilic derivatives of guanidine are provided as .are the methods of their use.
  • the .amphiphiles are capable of forming complexes with nucleic acids, and other biological compounds, and the nucleic acid complexes are capable of transforming mammalian cells.
  • the .amphiphiles of the invention .are non-toxic even when subjected to endogenous enzymatic processes.
  • Metabolizable amphiphilic derivatives of guanidine are provided which are useful as carriers for biologically active molecules, such as antibiotics or nucleic acids used in cell transformation processes.
  • biologically active molecules such as antibiotics or nucleic acids used in cell transformation processes.
  • the use of the amphiphilic materials as nucleic acid carriers is described in detail, since the compositions prepared using the amphiphiles are particularly efficacious for this purpose.
  • the amphiphiles are also useful in standard drug delivery regimens, such as for the delivery of antibiotics to the lungs of a patient.
  • complexes of the amphiphiles with DNA give rise to reduced amounts of toxic cleavage products when subject to the metabolic degradation process.
  • the invention in particular is directed to .amphiphilic derivatives of guanidine which are nontoxic themselves and which yield by-products, such as those produced by enzymatic cleavage, which .are nontoxic to a host organism or which are identical to substances endogenous to a host organism.
  • .amphiphiles thus offer the advantage that they can readily be used in humans, since they can be used repeatedly without the accumulation of toxic by-products.
  • amphiphilic compounds of the invention must be present in association with one or more anions, e.g., hydroxide, chloride, or bromide ions or more complex organic anions or bases.
  • anions e.g., hydroxide, chloride, or bromide ions or more complex organic anions or bases.
  • the particular anion associated with an amphiphilic cation is not critical to the formation or utility of the amphiphilic cation and may exchange (in whole or part) for other anions during use of the composition. Accordingly, the amphiphilic compounds of the invention are described in this specification generally in terms of the cation without reference to any particular anion. However, a number of specific examples are given, as well as general guidance for selection of anions.
  • chloride is the preferred anion; also acceptable are bromide or other physiologically acceptable anions including acetate, succinate and citrate.
  • the cations are either nontoxic themselves, and/or they yield by-products, for example, enzymatic cleavage products, which are nontoxic to a host organism or which are endogenous to a host organism. Generally, both the original lipids and their degradation products are nontoxic to a host organism.
  • the invention particularly relates to novel nitrogen-containing amphiphilic compounds having the formula:
  • each R independently is a straight-chain, aliphatic hydrocarbyl group of 5 to 29 carbon atoms inclusive, each X is -CH 2 - or -CO-, each m is an integer from 0 to 7 inclusive .and each n is zero or 1, with the proviso that when n is 1, the total number of carbon atoms in R and -(CH ⁇ ) m - is at least 10, and when n is zero, each R independently is a straight-chain, aliphatic hydrocarbyl group of at least 11 carbon atoms inclusive.
  • Preferred derivatives of the above formula I are those wherein n is 1.
  • each R independently has from 13 to 23 carbon atoms inclusive.
  • the R groups are saturated or are unsaturated having one or more ethylenically unsaturated linkages and are suitably the same or are different from each other.
  • X is -CO-, in which case illustrative R groups together with the -CO- group to which it is attached (i.e., R-CO-) include lauroyl, myristoyl, palmitoyl, stearoyl, linoleoyl, eicosanoyl, and nonacosanoyl (derived from the fatty acids of the corresponding name: lauric, myristic, etc.).
  • X can be -CH 2 -.
  • R groups alone, the corresponding names of the hydrocarbyl group derived from lauric acid is undecyl; from myristic acid, tridecyl; from palmitic acid, pentadecyl; from stearic acid, heptadecyl; from linoleic acid, cis,cis-8,ll-heptadecydienyl; from eicosanoic acid, nonadecyl; from tricosanoic acid, dicosanyl; and from hemicosanoyl, nonacosanyl.
  • This grouping of R groups is preferred when n is 1.
  • R is preferably the entire hydrocarbyl portion of a fatty alcohol, such as a lauryl, stearyl, or myristyl group.
  • R has the previously stated meaning.
  • Illustrative of such compounds are N,N-distearylguanidine, alternatively named amidinodioctadecylamine, N,N-dilaurylguanidine, alternatively named amidinodidodecylamine, and N,N-dimyristylguanidine, alternatively named amidinodi(tetradecyl)amine.
  • Other illustrative compounds of the above formula II will be apparent from the formula and the above meaning of R.
  • the compounds are of the formula
  • R, X and m have the previously stated meanings.
  • Such compounds are illustrated by N,N-di[2-(palmitoyloxy)ethyl]guanidine, alternatively named amidino-di[2-(hecadecanoyloxy)ethyl]amine, by N,N-di[2 (oleoyloxy)ethyl]guanidine, alternative named amidino[2-(9-octadecenoyloxy)ethyl]amine, .and by N,N ⁇ di[6-(stearoyloxy)hexyl]guanidine, alternatively named amidinodi[6-(octad; inoyloxy)hexyl]amine.
  • a general synthesis that can be used to produce compounds of the invention involves the conversion of a dialkanolamine to a diacyl derivative (after protecting the amine), deprotection of the amine, and reaction of the resulting secondary amine with cyanamide in base to provide the desired product.
  • the initial dialkanolamine can be obtained commercially (diethanolamine is readily available in quantity and is inexpensive) or can be synthesized by standard dialkylation reactions for the production of secondary amines from hydroxy-protected omega-hydroxyalkylhalides.
  • Omega- hydroxyalkylhalides are themselves available from the corresponding alpha, omega- dihydroxyalkanes, which can be readily prepared from cycloalkenes by oxidation
  • acyl groups are available from the acid halides (or anhydrides) of the corresponding carboxylic acids, which, as previously indicated, are preferably fatty acids and thus available commercially.
  • the general methods are not suitable for producing the amphiphiles of the present invention. For example, the reaction of secondary aliphatic amines with bromocyanide will form the corresponding cyanidamine, which then has been reported to form a substituted guanidine on reaction with ammonium chloride; however, the second step of this procedure did not work for making the compounds described herein.
  • the cationic lipids of the invention are typically used as carriers for various biological molecules, such as antibiotics or nucleic acids.
  • the cationic lipids can be used alone or combined with other lipids in formulations for the preparation of lipid vesicles or liposomes for use in intracellular delivery systems.
  • Uses contemplated for the lipids of the invention include transfection procedures corresponding to those presently known that use amphiphilic lipids, including those using commercial cationic lipid preparations, such as Lipofectin TM, and various other published techniques using conventional cationic lipid technology and methods.
  • the cationic lipids of the invention can be used in pharmaceutical formulations to deliver therapeutic agents by various routes and to various sites in an animal body to achieve a -desired therapeutic effect.
  • compositions of the present invention will minimally be usesble in the manner described in the patent, although operating parameters may need to be modified in order to achieve optimum results, using the specific information provided for compounds of the invention in this specification along with the knowledge of a person skilled in the arts of lipid preparation and use.
  • the lipids of the present invention are particularly useful and advantageous in the transfection of animal cells by genetic material. Additionally, since these compositions are non-toxic even when subjected to host enzymatic reactions, the compositions provide a number of advantages in the area of low toxicity when compared to previously known cationic lipids. These and other advantages of the invention are discussed in detail below. The remainder of this discussion is directed principally to selection, production, and use parameters for the cationic lipids of the present invention that may not immediately be apparent to one of ordinary skill in the art.
  • a lipid mixture used as a carrier can be modified in a variety of ways.
  • a lipid mixture is intended a formulation prepared from the cationic amphiphile of the invention, with or without additional agents such as steroids, and includes liposomes, interleaved bilayers of lipid, and the like.
  • Steroids e.g. cholesterol or ergosterol, can be used in combination with the cationic amphiphiles when used to prepare mixtures.
  • the lipid mixture will have from 0-67 mole percent steroid, preferably about 33 to 50 mole percent steroid.
  • a lipid-DNA complex is the composition obtained following combination of DNA and a lipid mixture.
  • Non-lipid material such as biological molecules being delivered to an animal or plant cell or target-specific moieties
  • Various linking groups can be sed for joining the lipid chains to the compound.
  • Functionalities of particular interest include thioethers, disulfides, carboxamides, alkylamines, ethers, and the like, used individually or in combination.
  • the active compounds to be bound to the lipid mixture ligands or receptors ca ble of binding to some biological molecule of interest is present in the targ f 1.
  • a iigand can be any compound of interest which can specifically bind to a* er compound, referred to •: a receptor, the Iigand and receptor forming a complementary pair.
  • the active compounds bound to the lipid mixture can vary widely, from small haptens (molecular weights of about 125 to 2,000) to antigens which will generally have molecular weights of at least about 6.000 and generally less than about 1 million, more usually less than about 300,000.
  • proteinaceous ligands and receptors that have specific complementary binding partners on cell surfaces.
  • Illustrative active compounds include chorionic gonadotropin, encepH ⁇ on, endorphin, luteinizing hormone, morphine, epinephrine, interferon, ACT..-, and polyiodothyronines and fragments of such compounds that retain the ability to bind to the same cell- surface binding partners that bind the original (non-fragment) molecules.
  • the number of targeting molecules (either Iigand or receptor) bound to a lipid mixture will vary with the size of the liposome, the size of the molecule, the binding affinity of the molecule to the target cell receptor or Iigand, and the like.
  • the bound active molecules will be present in the lipid mixture in from about 0.05 to 2 mole percent, more usually from about 0.01 to 1 mole percent based on the percent of bound molecules to the total number of molecules available in the mixture for binding.
  • receptors The surface membrane proteins which bind to specific effector molecules (usually soluble molecules in the external environment of the cell) are referred to as receptors.
  • receptors include antibodies and immunoglobulins since these molecules are found on the surface of certain cells.
  • the antibodies and immunoglobulins bound to a liposome containing a cationic lipid of the invention can also be considered to be ligands.
  • the immunoglobulins may be monoclonal or polyclonal, preferably monoclonal. Usually the immunoglobulins will be IgG and IgM, although the other immunoglobulins may also find use, such as IgA, IgD, and IgE.
  • the intact immunoglobulins may be used or only fragments thereof, such as Fab, F(ab') 2j F ( seemingly or F v fragments as well as a complete light or heavy chain.
  • antibodies of interest are those that bind to surface membrane antigens such as those antigens comprising the major histocompatibility complex, particularly the HLA-A, -B, -C and -D.
  • surface antigens include thy-l,leu-5, and la.
  • the cationic amphiphiles are particularly useful as carriers for anionic compounds, particularly polyanionic macromolecules such as nucleic acids. Where the amphiphiles are intended for use in vivo, particularly in vivo in humans, or where it is necessary to use the amphiphiles repeatedly, it is important to screen the carriers for those which are metabolized to non-toxic by-products and which themselves are not toxic or those which are eliminated from the body without degradation. The elimination of such cationic amphiphiles from tissues can be demonstrated in animal experiments. An animal, such as a mouse, can be administered one or more doses of material containing between 0.5 and 10 pmole of the lipid to be tested, complexed with an active component (such as DNA) if desired. At various times after administration, the animals are sacrificed, tissues taken, total lipids extracted using an appropriate solvent extraction system, and the total lipid analyzed for the particular cationic lipid or its partial degradation product using, for example, HPLC.
  • an active component such as DNA
  • the cationic amphiphiles are positively charged, and a tight charge complex can be formed between a cationic lipid carrier and a polyanionic nucleic acid, resulting in a lipid carrier-nucleic acid complex which can be used directly for systemic delivery to a mammal or mammalian cell.
  • the charge complex will withstand both the forces of nebulization and the environment within the lung airways and be capable of transfecting lung cells after the aerosolized DNA:lipid carrier complex has been deposited in the lung following intranasal or intraoral delivery of the aerosolized complex.
  • the first step is to identify lipid carriers and the concentration of lipid carrier-nucleic acid complexes that do not aggregate when the components are combined or during the significant agitation of the mixture that occurs during the nebulization step.
  • the second step is to identify among those lipids that do not aggregate those complexes that provide for a high level of transfection and transcription of a gene of interest in target cells in the lung.
  • a reporter gene CAT (which encodes chloramphenicol acetyltransferase) can be inserted in an expression cassette and used to evaluate each lipid carrier composition of interest.
  • the DNA:lipid carrier complexes are mixed in solutions which do not themselves induce aggregation of the DNA:lipid carrier complexes, such as sterile water.
  • the expression cassette (DNA) is mixed together with each of the lipid carriers to be tested in multiple different ratios, ranging as an example from 4:1 to 1:10 (micrograms of DNA to nanomoles of cationic lipid or total lipid, if a lipid mixture is present).
  • the optimal DNA:lipid carrier ratios for lipid mixtures such as N-[l-(2,3-dioleyloxy)- propyl]-N,N,N-triethylammonium chloride(DOTMA):dioleoylphosphatidylethanol- amine(DOPE) (the components of this mixture being present in a 1:1 weight ratio) and dimethyl dioctadecyl ammonium bromide (DDAB): Cholesterol (1:1) are 1 to 1.
  • DOTMA lamoleyloxy
  • DOPE dioleoylphosphatidylethanol- amine
  • DDAB dimethyl dioctadecyl ammonium bromide
  • the DNA:lipid carrier ratio is preferably in the range of from 1.5:1 to 2:1.
  • the cationic amphiphile is used for injection, then it need be evaluated only for whether it is effective for transfection of a target cell.
  • Particular cells can be targeted by the use of particular cationic lipids for preparation of the lipid-mixture carriers, for example, by the use of E-DMPC to target lung cells preferentially, or by modifying the amphiphiles to direct them to particular types of cells using site-directing molecules.
  • antibodies or ligands for particular receptors may be employed, to target a cell associated with a particular surface protein.
  • a particular Iigand or antibody can be conjugated to the cationic amphiphile in accordance with conventional techniques, either by conjugating the site-directing molecule to a lipid for incorporation into the lipid bilayer or by providing a linking group on a lipid present in the bilayer for linking to a functionality of the site-directing compound. Such techniques are well known to those skilled in the art.
  • the various lipid carrier-nucleic acid complexes wherein the lipid carrier is a liposome are prepared using methods well known in the art. Mixing conditions can be optimized by visual examination of the resultant lipid-DNA mixture to establish that no precipitation occurs. To make the lipid-DNA complexes more visible, the complexes can be stained with a dye which does not itself cause aggregation, but which will stain either the DNA or the lipid. For example, Sudan black (which stains lipid) can be used as an aid to examine the lipid-DNA mixture to determine if aggregation has occurred. Particle size also can be studied with methods known in the art, including electron microscopy, laser light scattering, CoulterTM counting/sizing, and the like.
  • Standard-size beads can be included as markers for determining the size of any liposomes or aggregates that form.
  • lipid carrier-nucleic acid complex is meant a nucleic acid sequence as described above, generally bound to the surface of a lipid carrier preparation, as discussed below.
  • the lipid carrier preparation can also include other substances, such as enzymes necessary for integration, transcription and translation or cofactors.
  • the lipid carrier-nucleic acid complex can include targeting agents to deliver the complex to particular cell or tissue types.
  • the nucleic acid material is added to a suspension of preformed liposomes which may be multi-lamellar vesicles (MLVs) or small unilamellar vesicles (SUVs), usually SUVs formed by sonication.
  • MLVs multi-lamellar vesicles
  • SUVs small unilamellar vesicles
  • the liposomes themselves are prepared from a dried lipid film that is resuspended in an appropriate mixing solution such as sterile water or an isotonic buffer solution such as lOmM Tris/NaCl or 5 % dextrose in sterile water and sonicated to form the liposomes. Then the preformed lipid carriers are mixed directly with the DNA.
  • an appropriate mixing solution such as sterile water or an isotonic buffer solution such as lOmM Tris/NaCl or 5 % dextrose in sterile water and sonicated to form the liposomes.
  • an isotonic buffer solution such as lOmM Tris/NaCl or 5 % dextrose in sterile water
  • lipid-DNA complex can be critically affected by the sequence in which the lipid and DNA are combined. Generally, it is preferable (to minimize aggregation) to add the lipid to the DNA at ratios of DNA:lipid of up to 1:2 inclusive (microgram DNA:nanomoles cationic lipid). Where the ratio of DNA:lipid is 1:4 or higher, better results are generally obtained by adding the DNA to the lipid. In either case, mixing should be rapidly achieved by shaking or vortexing for small volumes and by use of rapid mixing systems for l ⁇ urge volumes.
  • the lipid carrier and DNA form a very stable complex due to binding of the negatively charged DNA to the cationic lipid carriers. SUVs find use with small nucleic acid fragments as well as with large regions of DNA ( ⁇ 250kb).
  • lipid carrier-nucleic acid complex Aggregation of the lipid carrier-nucleic acid complex is prevented by controlling the ratio of DNA to lipid carrier, minimizing the overall concentration of DNA:lipid carrier complex in solution, usually less than 5 mg DNA/8 ml solution, and avoiding the use of chelating agents such as EDTA and/or significant amounts of salt, either of which tends to promote macro-aggregation.
  • the preferred excipient is water, dextrose/water or another lution having low or zero ionic strength.
  • the volume should be adjusted to the minimum necessary for deposition in the lungs of the host mammal, while at the same time taking care not to make the solution too concentrated so that aggregates form.
  • Increasing the volume of the solution is to be avoided if possible due to the need to increase the inhalation time for the host animal to accommodate the increased volume.
  • Such materials are prepared as complexes as described above, except that a cryoprotectant such as mannitol or trehalose is included in the buffer solution which is used for preparation of the lipid carrier-DNA complexes. Any glucose generally included in such a buffer is preferably omitted.
  • the lipid carrier complex is rapidly freeze-dried following mixing of the lipid and DNA. The mixture can be reconstituted with sterile water to yield a composition which is ready for administration to a host animal.
  • the liposomes may be sized in accordance with conventional techniques, depending upon the desired size.
  • a large liposome injected into the bloodstream of an animal has higher affinity for lung cells as compared to liver cells. Therefore, the particular size range may be evaluated in accordance with any intended target tissue by administering lipid-nucleic acid complexes of varying particle sizes to a host animal and determining the size of particle which provides the desired results.
  • the cationic amphiphiles complexed with nucleic acid of this invention can be administered in a variety of ways to a host, such as intravenously, intramuscularly, subcutaneously, transdermally, topically, intraperitoneally, intravascularly, by aerosol, following nebulization, and the like.
  • the amphiphiles will be injected in solution where the concentration of compound bound to or entrapped in the liposome will dictate the amount to be administered. This amount will vary with the effectiveness of the compound being administered, the required concentration for the desired effect, the number of administrations, and the like.
  • the lipid-DNA complexes can be administered in the form of a lyophilized powder.
  • the amphiphiles Upon administration of the amphiphiles, when a targeting moiety is used, the amphiphiles preferentially bind to a cell surface factor complementary to the compounds bound to the liposome. If no targeting moiety is bound to the liposome, then it binds to cell surface by lipophilic interactions. The liposomes normally are transferred into the cell by endocytosis.
  • the cationic amphiphiles find use for complexing with nucleic acid or protein for transporting these macromolecules in vivo.
  • the nucleic acid can include DNA, RNA, antisense RNA or other antisense molecules.
  • Cationic amphiphiles that form liposomes also find use in drug delivery, where the drug can be entrapped within the liposome or bound to the outside.
  • N-BOC ester 2 To 3.5 g (0.086 mol) of N-BOC ester 2 were added 20 ml of 4M solution of HCI in dioxane and mixture was stirred at R.T. for 2 hrs. The resulting suspension was evaporated on rotavapor, diluted with ether (50 ml), filtered, washed with ether (25 mlx2) and dried in vacuum to get 3.1 g (97%) of amino ester 4.
  • Liposomes containing ADODE, ADPDE or ADS in a 1:1 molar ratio with cholesterol were tested as DNA carriers for gene transfer and expression in mice.
  • the plasmid used was pZN51. The methods and plasmids used are described in more detail in WO93/24640.
  • the liposomes were in a lOmM stock in 5% dextrose.
  • the liposome:plasmid DNA ratios were screened for the presence of aggregation. Ratios from 1:2 to 1:7 ( ⁇ g plasmid DNA to nanomoles cationic lipid) were screened. DNA:liposome ratios that did not produce aggregation were then tested in mice. 100 ⁇ g of pZN51 was complexed to 500 nanomoles of
  • DDABrcholesterol liposomes as a positive control and an uninjected mouse served as the negative control (N).
  • ICR female mice 25 g were used for the in vivo studies.
  • a dose of 100 ⁇ g plasmid DNA in 200 ⁇ l 5% dextrose in water was injected by tail vein per mouse.
  • the lung, heart, liver, kidney and spleen were removed after 24 hours. Each organ was homogenized in 0.3 ml of 0.25 M Tris-HCl pH7.8, 5 mM EDTA, and the resulting extract was centrifuged and then subjected to 3 cycles of freeze-thaw and then treated to 65 °C for 20 min.
  • the protein concentration of lung, heart, liver and kidney extracts were quantitated using a ninhydrin-based protein assay (Bio-Rad, Berkeley, CA), and same amount of total protein from each tissue extract was added in the CAT assay, together with 10 ⁇ l of 20 mM acetyl CoA+12 l of 14 C-chloramphemcol (25 ⁇ Ci/ml, 55 mCi/mmole, Amersham)), at 37 ° C for 13 hrs.
  • ADODE:CHOL liposomes in a 1:6 ratio produced the highest levels of
  • CAT activity in the lung, heart, liver, kidney and spleen was similar to DDAB:CHOL in a 1:5 ratio in these organs.
  • ADS:CHOL liposomes in a 1:5 ratio produced the highest levels of CAT activity in the lung and liver.
  • the CAT activity was lower than that produced by DDAB:CHOL at the 1:5 ratio.
  • DDAB:CHOL In heart, spleen and kidney ADS:CHOL produces little to no CAT activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à des amphiphiles à base de guanidine non toxiques pour un mammifère hôte, en particulier l'homme. Ces amphiphiles sont utilisés pour produire des liposomes aptes à être utilisés comme vecteurs destinés à l'apport intracellulaire de macromolécules.
PCT/US1994/013428 1993-11-24 1994-11-17 Derives amphiphiles de guanidine WO1995014381A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1019960702743A KR960705771A (ko) 1993-11-24 1994-11-17 구아니딘의 양쪽친화성 유도체(amphiphilic derivatives of guanidine)
AU11842/95A AU691226B2 (en) 1993-11-24 1994-11-17 Amphiphilic derivatives of guanidine
JP7515172A JPH09505808A (ja) 1993-11-24 1994-11-17 グアニジンの両親媒性誘導体
EP95902642A EP0730405A4 (fr) 1993-11-24 1994-11-17 Derives amphiphiles de guanidine
NZ276975A NZ276975A (en) 1993-11-24 1994-11-17 Guanidine based amphiphiles and their use in liposomes for delivering genetic material intracellularly
NO962074A NO962074L (no) 1993-11-24 1996-05-21 Amfifiliske derivater av guanidin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15772793A 1993-11-24 1993-11-24
US24800594A 1994-05-24 1994-05-24
US08/248,005 1994-05-24
US08/157,727 1994-05-24

Publications (1)

Publication Number Publication Date
WO1995014381A1 true WO1995014381A1 (fr) 1995-06-01

Family

ID=26854424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013428 WO1995014381A1 (fr) 1993-11-24 1994-11-17 Derives amphiphiles de guanidine

Country Status (8)

Country Link
EP (1) EP0730405A4 (fr)
JP (1) JPH09505808A (fr)
KR (1) KR960705771A (fr)
AU (1) AU691226B2 (fr)
CA (1) CA2176715A1 (fr)
NO (1) NO962074L (fr)
NZ (1) NZ276975A (fr)
WO (1) WO1995014381A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779361A2 (fr) 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Forme tronquée de la protéine inhibitrice kappa B, production récombinante et utilisation
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
WO1998014439A1 (fr) * 1996-10-03 1998-04-09 Vical Incorporated Cytofectines a base de piperazine
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5783565A (en) * 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
WO1998054130A1 (fr) * 1997-05-28 1998-12-03 Rhone-Poulenc Rorer S.A. Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US6034137A (en) * 1996-10-22 2000-03-07 Syntex (U.S.A.) Inc. Cationic lipids for gene therapy
US6143729A (en) * 1996-03-01 2000-11-07 Aventis Pharma S.A. Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6444321B1 (en) * 1995-12-01 2002-09-03 Forskarpatent I Syd Ab Reversibly, non-covalent bound surface coating
US6670332B1 (en) 1995-11-30 2003-12-30 Vical Incorporated Complex cationic lipids having quarternary nitrogens therein
WO2005123676A1 (fr) * 2004-06-17 2005-12-29 Ucl Business Plc Composes bi-guanidino-biphenyle ou tetra-guanidino-biphenyle servant de petites molecules porteuses
US7268120B1 (en) 1997-11-20 2007-09-11 Vical Incorporated Methods for treating cancer using cytokine-expressing polynucleotides
WO2015009829A2 (fr) 2013-07-16 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Amélioration du potentiel ostéogénique des greffons osseux

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Volume 249, issued 14 September 1990, E.G. NABEL et al., "Site-Specific Gene Expression In Vivo by Direct Gene Transfer Into Arterial Wall", pages 1285-1288. *
See also references of EP0730405A4 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5747471A (en) * 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) * 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5783565A (en) * 1994-12-09 1998-07-21 Genzyme Corporation Cationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic molecules
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US6344446B1 (en) 1995-06-07 2002-02-05 Valentis, Inc. Cationic lipid:DNA complexes for gene targeting
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US8541628B2 (en) 1995-11-30 2013-09-24 Vical Incorporated Complex cationic lipids having quaternary nitrogens therein
US6670332B1 (en) 1995-11-30 2003-12-30 Vical Incorporated Complex cationic lipids having quarternary nitrogens therein
US6444321B1 (en) * 1995-12-01 2002-09-03 Forskarpatent I Syd Ab Reversibly, non-covalent bound surface coating
EP0779361A2 (fr) 1995-12-15 1997-06-18 F. Hoffmann-La Roche Ag Forme tronquée de la protéine inhibitrice kappa B, production récombinante et utilisation
US6143729A (en) * 1996-03-01 2000-11-07 Aventis Pharma S.A. Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6022874A (en) * 1996-10-03 2000-02-08 Vical Incorporated Piperazine based cytofectins
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
WO1998014439A1 (fr) * 1996-10-03 1998-04-09 Vical Incorporated Cytofectines a base de piperazine
US6034137A (en) * 1996-10-22 2000-03-07 Syntex (U.S.A.) Inc. Cationic lipids for gene therapy
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US6300321B1 (en) * 1997-05-28 2001-10-09 Aventis Pharma S.A. Compounds, preparation and use for transferring nucleic acids into cells
WO1998054130A1 (fr) * 1997-05-28 1998-12-03 Rhone-Poulenc Rorer S.A. Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
US7268120B1 (en) 1997-11-20 2007-09-11 Vical Incorporated Methods for treating cancer using cytokine-expressing polynucleotides
EP1987845A2 (fr) 1997-11-20 2008-11-05 Vical Incorporated Traitement contre le cancer utilisant des polynucléotides à expression cytokine et compositions correspondantes
US7470675B2 (en) 1997-11-20 2008-12-30 Vical Incorporated Methods for treating cancer using interferon-ω-expressing polynucleotides
WO2005123676A1 (fr) * 2004-06-17 2005-12-29 Ucl Business Plc Composes bi-guanidino-biphenyle ou tetra-guanidino-biphenyle servant de petites molecules porteuses
WO2015009829A2 (fr) 2013-07-16 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Amélioration du potentiel ostéogénique des greffons osseux

Also Published As

Publication number Publication date
CA2176715A1 (fr) 1995-06-01
AU691226B2 (en) 1998-05-14
NO962074L (no) 1996-07-11
NZ276975A (en) 1998-04-27
KR960705771A (ko) 1996-11-08
EP0730405A4 (fr) 1997-02-19
AU1184295A (en) 1995-06-13
EP0730405A1 (fr) 1996-09-11
JPH09505808A (ja) 1997-06-10
NO962074D0 (no) 1996-05-21

Similar Documents

Publication Publication Date Title
AU691226B2 (en) Amphiphilic derivatives of guanidine
US5776908A (en) Amphiphilic derivatives of piperazine
EP0730404B1 (fr) Derives amphiphiles d'imidazolinium
AU696881B2 (en) Cationic amphiphiles
US5958894A (en) Amphiphilic biguanide derivatives
US5811406A (en) Dry powder formulations of polynucleotide complexes
US5902802A (en) Cationic amphiphiles
EP0523189B1 (fr) Lipides cationiques servant a l'apport intracellulaire de molecules biologiquement actives
EP1019365B1 (fr) Nouvelles compositions d'administration de molecules chargees negativement
AU707734B2 (en) Stabilization of polynucleotide complexes
US6245520B1 (en) Methods for introducing nucleic acids into mammalian cells using imidazolium lipids
US5665879A (en) Amphiphilic derivatives of piperazine
WO2001042200A1 (fr) Amphiphiles cationiques pour administration intracellulaire de molecules therapeutiques
AU720187B2 (en) Gene therapy using polynucleotide complexes
AU2921102A (en) Gene therapy using polynucleotide complexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2176715

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 276975

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995902642

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995902642

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1995902642

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995902642

Country of ref document: EP